Recent Research Analysts’ Ratings Updates for Illumina (ILMN)

Illumina (NASDAQ: ILMN) recently received a number of ratings updates from brokerages and research firms:

• 5/4/2026 – Illumina had its price target raised by Citigroup Inc. from $80.00 to $95.00. They now have a “sell” rating on the stock.
• 5/1/2026 – Illumina had its “outperform” rating reaffirmed by Evercore Inc.
• 5/1/2026 – Illumina had its price target lowered by Canaccord Genuity Group Inc. from $150.00 to $140.00. They now have a “hold” rating on the stock.
• 5/1/2026 – Illumina had its price target raised by Barclays PLC from $110.00 to $122.00. They now have an “underweight” rating on the stock.
• 5/1/2026 – Illumina had its price target raised by JPMorgan Chase & Co. from $120.00 to $125.00. They now have a “neutral” rating on the stock.
• 4/29/2026 – Illumina was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.

Insider Activity at Illumina

In related news, SVP Patricia Leckman sold 2,370 shares of Illumina stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total transaction of $275,346.60. Following the completion of the sale, the senior vice president owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. The trade was a 12.68% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 2.90% of the company’s stock.

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.